Arthur D. Little Publishes Special 135th Anniversary Edition of PRISM Magazine
17.12.2021 17:11:00 EET | Business Wire | Press release
Arthur D. Little (ADL) has published Who Says It Can’t Be Done? – the latest edition of its innovation magazine PRISM. As well as celebrating the company’s 135-year history, this special edition looks ahead to both the future of business and the consulting industry itself.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005298/en/
Arthur D. Little Prism Magazine (Photo: Business Wire)
The magazine features five key articles:
- Rebalancing For Tomorrow – The ability to help clients anticipate the future, embrace new opportunities, and transform their operations has always been a central part of ADL’s consulting philosophy. This article looks at the challenges that business faces today, identifies important priorities for the future, and reflects on how companies can get ready to meet them.
- Why Consultancy Matters: A Historical Perspective – What is the exact nature of management consultancy’s value? Does consulting merely provide a similar service to that of the accountancy or legal professions, or does it provide a different type of value? This article explores how management consultancy has helped to shape the world we live in today as illustrated by the history of ADL.
- The Future Of Consultancy – In today’s volatile environment, companies are looking for more than just me-too solutions to remain competitive. The consulting industry needs to reconfigure its approach and reject obsolete legacy models if it is to stay relevant to modern business. This article looks at some of the ways in which consulting must change in order to create real value for its clients.
- Inventors, Innovators, Pathfinders – Since the days of Arthur Dehon Little himself, ADL has been driven by hugely talented individuals, all pathfinders in their own right. This article celebrates some of the extraordinary people who have both led ADL and pioneered its unique approach to consultancy, inventing new solutions and breaking down barriers along the way.
- Who Says It Can’t Be Done? – It was only after a management buyout (MBO) on 30 December 2011 that ADL was truly reborn as a successful partnership with a rapidly expanding business. In this interview with Ignacio Garcia-Alves, who led the MBO and has been ADL’s Chief Executive Officer ever since, he shares his insights on how the company was transformed and the lessons learned over the past ten years.
Ignacio García Alves, Global Chairman and Chief Executive Officer of Arthur D. Little, comments: “PRISM always offers the best in thought-leading insight and commentary on the key topics of the day, and this edition is no exception – but with ADL hitting the milestone of 135 years of constant innovation, we couldn’t resist also looking back on what’s made it such a unique and pioneering company.”
This latest edition of PRISM can be viewed here: https://tinyurl.com/9hyefpch
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005298/en/
Contact information
Further information from: Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom